Stacy M Medical treatment of Parkinson disease Neurol Clin 2009 27 3 605-631 
Tanner CM Ross GW Jewell SA Occupation and risk of parkinsonism: a multicenter case-control study Arch Neurol 2009 66 9 1106-1113 
US interim projections by age, sex, race, and hispanic origin: 2000&#8211;2050 Available from:
Cotzias GC Papavasiliou PS Gellene R Modif ication of Parkinsonism &#8211; chronic treatment with L-dopa N Engl J Med 1969 280 7 337-345 
Lang AE Lozano AM Parkinson&#8217;s disease. First of two parts N Engl J Med 1998 339 15 1044-1053 
Nutt JG Motor fluctuations and dyskinesia in Parkinson&#8217;s disease Parkinsonism Relat Disord 2001 8 2 101-108 
Fahn S Oakes D Shoulson I Levodopa and the progression of Parkinson&#8217;s disease N Engl J Med 2004 351 24 2498-2508 
Fahn S The spectrum of levodopa-induced dyskinesias Ann Neurol 2000 47 Suppl 1 2-11 
Golbe LI Young-onset Parkinson&#8217;s disease: a clinical review Neurology 1991 41 2 Pt 1 168-173 
Forno LS Neuropathology of Parkinson&#8217;s disease J Neuropathol Exp Neurol 1996 55 3 259-272 
Jellinger KA Post mortem studies in Parkinson&#8217;s disease &#8211; is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999 56 1-29 
Grace AA Bunney BS The control of firing pattern in nigral dopamine neurons: single spike firing J Neurosci 1984 4 11 2866-2876 
Grace AA Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 1991 41 1 1-24 
Abercrombie ED Bonatz AE Zigmond MJ Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats Brain Res 1990 525 1 36-44 
Schultz W Predictive reward signal of dopamine neurons J Neurophysiol 1998 80 1 1-27 
Venton BJ Zhang H Garris PA Phillips PE Sulzer D Wightman RM Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing J Neurochem 2003 87 5 1284-1295 
Olanow CW Obeso JA Stocchi F Continuous dopamine-receptor treatment of Parkinson&#8217;s disease: scientific rationale and clinical implications Lancet Neurol 2006 5 8 677-687 
Lewitt PA Levodopa for the treatment of Parkinson&#8217;s disease N Engl J Med 2008 359 23 2468-2476 
Nutt JG Woodward WR Beckner RM Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 1994 44 5 913-919 
Nutt JG Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 2000 55 11 Suppl 4 S33-S37 
De la Fuente-Fern&#225;ndez R Sossi V Huang Z Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson&#8217;s disease: implications for dyskinesias Brain 2004 127 Pt 12 2747-2754 
Olanow CW Obeso JA Preventing levodopa-induced dyskinesias Ann Neurol 2000 47 4 Suppl 1 S167-S176 
Nutt JG Carter JH Lea ES Woodward WR Motor fluctuations during continuous levodopa infusions in patients with Parkinson&#8217;s disease Mov Disord 1997 12 3 285-292 
Stocchi F Vacca L Ruggieri S Olanow CW Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study Arch Neurol 2005 62 6 905-910 
Antonini A Isaias IU Canesi M Duodenal levodopa infusion for advanced Parkinson&#8217;s disease: 12-month treatment outcome Mov Disord 2007 22 8 1145-1149 
Pearce RK Banerji T Jenner P Marsden CD De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset Mov Disord 1998 13 2 234-241 
Rascol O Brooks DJ Korczyn AD de Deyn PP Clarke CE Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson&#8217;s disease who were treated with ropinirole or levodopa N Engl J Med 2000 342 20 1484-1491 
Olanow CW The scientific basis for the current treatment of Parkinson&#8217;s disease Annu Rev Med 2004 55 41-60 
Stocchi F Rascol O Kieburtz K Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study Ann Neurol 2010 68 1 18-27 
Smith LA Jackson MJ Al-Barghouthy G Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates Mov Disord 2005 20 3 306-314 
Suzuki K Nakazato H Matsui H Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population Cancer 2003 98 7 1411-1416 
Tanaka Y Sasaki M Shiina H Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer Cancer Epidemiol Biomarkers Prev 2006 15 2 238-244 
Shoulson I Glaubiger GA Chase TN On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients Neurology 1975 25 12 1144-1148 
Hardie RJ Lees AJ Stern GM On-off fluctuations in Parkinson&#8217;s disease. A clinical and neuropharmacological study Brain 1984 107 Pt 2 487-506 
Bredberg E Nilsson D Johansson K Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson&#8217;s disease Eur J Clin Pharmacol 1993 45 2 117-122 
Sage JI Schuh L Heikkila RE Duvoisin RC Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson&#8217;s disease Clin Neuropharmacol 1988 11 1 36-44 
Nyholm D Nilsson Remahl AI Dizdar N Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology 2005 64 2 216-223 
Nilsson D Nyholm D Aquilonius SM Duodenal levodopa infusion in Parkinson&#8217;s disease &#8211; long-term experience Acta Neurol Scand 2001 104 6 343-348 
Devos D Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson&#8217;s disease Mov Disord 2009 24 7 993-1000 
Nyholm D Pharmacokinetics of levodopa/carbidopa infusion with and without oral catechol-O-methyl transferase (COMT) inhibitors (DuoCOMT) Available from:
Pekkonen E Duodenal levodopa infusion, quality of life and autonomic nervous system in Parkinson&#8217;s disease Available from:
Lundqvist C Beiske A Continuous delivery of levodopa in patients with advanced idiopathic Parkinsons disease &#8211; cost-benefit Available from:
Nyholm D Different dyskinesias in Parkinson&#8217;s disease and their relation to levodopa pharmacokinetics (DYSK-PD-2007) Available from:
Kurlan R Rothfield KP Woodward WR Erratic gastric emptying of levodopa may cause &#8220;random&#8221; fluctuations of parkinsonian mobility Neurology 1988 38 3 419-421 
Djaldetti R Baron J Ziv I Melamed E Gastric emptying in Parkinson&#8217;s disease: patients with and without response fluctuations Neurology 1996 46 4 1051-1054 
Pfeiffer RF Gastrointestinal dysfunction in Parkinson&#8217;s disease Lancet Neurol 2003 2 2 107-116 
Goetze O Nikodem AB Wiezcorek J Predictors of gastric emptying in Parkinson&#8217;s disease Neurogastroenterol Motil 2006 18 5 369-375 
Steiger MJ Stocchi F Carta A The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon &#8220;off &#8221; periods in Parkinson&#8217;s disease Clin Neuropharmacol 1991 14 3 241-244 
Stocchi F Fabbri L Vecsei L Krygowska-Wajs A Monici Preti PA Ruggieri SA Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease Clin Neuropharmacol 2007 30 1 18-24 
Stocchi F Zappia M Dall&#8217;Armi V Kulisevsky J Lamberti P Obeso JA Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson&#8217;s disease Mov Disord 2010 25 12 1881-1887 
Chen D An exploratory study of XP21279 (with Lodosyn&#174;) and Sinemet&#174; in Parkinson&#8217;s disease subjects Available from:
Product candidates, XP21279 Available from:
Hsu A Verhagen Metman L Ellenbogen A Comparison of IPX066, a novel extended-release oral carbidopa-levodopa formulation, to immediate-release carbidopa-levodopa in patients with advanced Parkinson&#8217;s disease Am Acad Neurol 2010 74 Suppl 2 A350 
A study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson&#8217;s disease (APEX-PD) Available from:
Ferr&#233; S O&#8217;Connor WT Fuxe K Ungerstedt U The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain J Neurosci 1993 13 12 5402-5406 
Svenningsson P Le Moine C Aubert I Burbaud P Fredholm BB Bloch B Cellular distribution of adenosine A2A receptor mRNA in the primate striatum J Comp Neurol 1998 399 2 229-240 
Ferr&#233; S Fredholm BB Morelli M Popoli P Fuxe K Adenosine&#8211;dopamine receptor&#8211;receptor interactions as an integrative mechanism in the basal ganglia Trends Neurosci 1997 20 10 482-487 
Mori A Shindou T Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists Neurology 2003 61 11 Suppl 6 S44-S48 
Fenu S Pinna A Ongini E Morelli M Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats Eur J Pharmacol 1997 321 2 143-147 
Rose S Ramsay Croft N Jenner P The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats Brain Res 2007 1133 1 110-114 
Kanda T Jackson MJ Smith LA Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann Neurol 1998 43 4 507-513 
Lundblad M Vaudano E Cenci MA Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia J Neurochem 2003 84 6 1398-1410 
Kanda T Jackson MJ Smith LA Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp Neurol 2000 162 2 321-327 
Bara-Jimenez W Sherzai A Dimitrova T Adenosine A(2A) receptor antagonist treatment of Parkinson&#8217;s disease Neurology 2003 61 3 293-296 
Hauser RA Hubble JP Truong DD Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD Neurology 2003 61 3 297-303 
Lewitt PA Guttman M Tetrud JW Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces &#8220;off &#8221; time in Parkinson&#8217;s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Ann Neurol 2008 63 3 295-302 
Stacy M Silver D Mendis T A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease Neurology 2008 70 23 2233-2240 
Hauser RA Shulman LM Trugman JM Study of istradefylline in patients with Parkinson&#8217;s disease on levodopa with motor fluctuations Mov Disord 2008 23 15 2177-2185 
Guttman M Efficacy of istradefylline in Parkinson&#8217;s disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002 US-018 study Mov Disord 2006 21 Suppl 15 S585 
KW-6002 to treat Parkinson&#8217;s disease. NCT00006337 Available from:
2nd generation A2A antagonist Available from:
A phase 2, 12-week, double-blind, dose-finding, placebo-controlled study to assess the efficacy and safety of a range of SCH 420814 doses in subjects with moderate to severe Parkinson&#8217;s disease experiencing motor fluctuations and dyskinesias Available from:
Hauser RA Pourcher E Micheli F Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson&#8217;s disease Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders Paris, France 7&#8211;11 Jun 2009 Abstract Tu-185.
Huyck SB Wolski K Cantillon M Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson&#8217;s disease: post hoc analysis of dose-finding study Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders Paris, France 7&#8211;11 Jun 2009 Abstract Tu-187. 
A placebo- and active-controlled study of preladenant in early Parkinson&#8216;s disease (study P05664 AM2) Available from: 
A placebo- and active controlled study of preladenant in subjects with moderate to severe Parkinson&#8216;s disease (study P04938 AM2) Available from: 
Synosia Therapeutics Pipeline Available from: 
Sigma-Tau. Research development stages Available from: 
Ross GW Abbott RD Petrovitch H Association of coffee and caffeine intake with the risk of Parkinson disease JAMA 2000 283 20 2674-2679 
Ascherio A Zhang SM Hern&#225;n MA Prospective study of caffeine consumption and risk of Parkinson&#8217;s disease in men and women Ann Neurol 2001 50 1 56-63 
Tan EK Tan C Fook-Chong SM Dose-dependent protective effect of coffee, tea, and smoking in Parkinson&#8217;s disease: a study in ethnic Chinese J Neurol Sci 2003 216 1 163-167 
Hu G Bidel S Jousilahti P Antikainen R Tuomilehto J Coffee and tea consumption and the risk of Parkinson&#8217;s disease Mov Disord 2007 22 15 2242-2248 
Chen JF Xu K Petzer JP Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson&#8217;s disease J Neurosci 2001 21 10 RC143 
Ikeda K Kurokawa M Aoyama S Kuwana Y Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson&#8217;s disease J Neurochem 2002 80 2 262-270 
Pierri M Vaudano E Sager T Englund U KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse Neuropharmacology 2005 48 4 517-524 
Jenner P Mori A Hauser RA Morelli M Fredholm BB Chen JF Adenosine, adenosine A2A antagonists, and Parkinson&#8217;s disease Parkinsonism Relat Disord 2009 15 6 406-413 
Blandini F Armentero MT Fancellu R Blaugrund E Nappi G Neuroprotective effect of rasagiline in a rodent model of Parkinson&#8217;s disease Exp Neurol 2004 187 2 455-459 
Kupsch A Sautter J G&#246;tz ME Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline J Neural Transm 2001 108 8&#8211;9 985-1009 
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 2004 61 4 561-566 
Olanow CW Rascol O Hauser RA A double-blind, delayed-start trial of rasagiline in Parkinson&#8217;s disease N Engl J Med 2009 361 13 1268-1278 
Kieburtz K ADAGIO misses a beat? Lancet Neurol 2009 8 12 1081-1082 
Ahlskog JE Uitti RJ Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010 74 14 1143-1148 
Marzo A Dal Bo L Monti NC Pharmacokinetics and pharmacodynamics of saf inamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity Pharmacol Res 2004 50 1 77-85 
Caccia C Maj R Calabresi M Safinamide: from molecular targets to a new anti-Parkinson drug Neurology 2006 67 7 Suppl 2 S18-S23 
Stocchi F Arnold G Onofrj M Improvement of motor function in early Parkinson disease by safinamide Neurology 2004 63 4 746-748 
Borgohain R Szasz J Bhatt M Efficacy and safety of safinamide in patients with Parkinson&#8217;s disease experiencing motor fluctuations: results of a 6-month phase III, randomized, double-blind, placebo-controlled study 2009 Available from:
Willmer J Safinamide in levodopa induced dyskinesia in Parkinson&#8217;s disease subjects (safinamide-LID) Available from:
Schapira AH Safinamide in the treatment of Parkinson&#8217;s disease Expert Opin Pharmacother 2010 11 13 2261-2268 
Stacy M Galbreath A Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia Clin Neuropharmacol 2008 31 1 51-56 
Hauser RA Rascol O Korczyn AD Ten-year follow-up of Parkinson&#8217;s disease patients randomized to initial therapy with ropinirole or levodopa Mov Disord 2007 22 16 2409-2417 
Holloway R Marek K Biglan K Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease Arch Neurol 2009 66 5 563-570 
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 2002 287 13 1653-1661 
Whone AL Watts RL Stoessl AJ Slower progression of Parkinson&#8217;s disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 2003 54 1 93-101 
Schapira AH Albrecht S Barone P Immediate vs delayed-start pramipexole in early Parkinson&#8217;s disease: the PROUD study Parkinsonism Relat Disord 2009 15 Suppl 2 S81 
Schapira AH Albrecht S Barone P Rationale for delayed-start study of pramipexole in Parkinson&#8217;s disease: the PROUD study Mov Disord 2010 25 11 1627-1632 
Stocchi F Hersh BP Scott BL Nausieda PA Giorgi L Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson&#8217;s disease: a randomized, double-blind, non-inferiority crossover study Curr Med Res Opin 2008 24 10 2883-2895 
Pahwa R Stacy MA Factor SA Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease Neurology 2007 68 14 1108-1115 
Hersh BP Earl NL Hauser RA Stacy M Early treatment benefits of ropinirole prolonged release in Parkinson&#8217;s disease patients with motor fluctuations Mov Disord 2010 25 7 927-931 
Hauser RA Schapira AH Rascol O Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson&#8217;s disease Mov Disord 2010 25 15 2542-2549 
Driver-Dunckley E Samanta J Stacy M Pathological gambling associated with dopamine agonist therapy in Parkinson&#8217;s disease Neurology 2003 61 3 422-423 
Weintraub D Siderowf AD Potenza MN Association of dopamine agonist use with impulse control disorders in Parkinson disease Arch Neurol 2006 63 7 969-973 
Voon V Hassan K Zurowski M Prevalence of repetitive and reward-seeking behaviors in Parkinson disease Neurology 2006 67 7 1254-1257 
Evans AH Strafella AP Weintraub D Stacy M Impulsive and compulsive behaviors in Parkinson&#8217;s disease Mov Disord 2009 24 11 1561-1570 
Weintraub D Koester J Potenza MN Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Arch Neurol 2010 67 5 589-595 
Thomas A Bonanni L Gambi F di Iorio A Onofrj M Pathological gambling in Parkinson disease is reduced by amantadine Ann Neurol 2010 68 3 400-404 
Weintraub D Sohr M Potenza MN Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study Ann Neurol 2010 68 6 963-968 
Weintraub D Naltrexone for impulse control disorders in Parkinson&#8216;s disease Available from:
Modi G Pillay V Choonara YE Advances in the treatment of neurodegenerative disorders employing nanotechnology Ann N Y Acad Sci 2010 1184 154-172 
Modi G Pillay V Choonara YE Ndesendo VM du Toit LC Naidoo D Nanotechnological applications for the treatment of neurodegenerative disorders Prog Neurobiol 2009 88 4 272-285 
Staples M Microchips and controlled-release drug reservoirs Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010 2 4 400-417 
Linazasoro G Potential applications of nanotechnologies to Parkinson&#8217;s disease therapy Parkinsonism Relat Disord 2008 14 5 383-392 
Bergman H Wichmann T DeLong MR Reversal of experimental parkinsonism by lesions of the subthalamic nucleus Science 1990 249 4975 1436-1438 
Aziz TZ Peggs D Sambrook MA Crossman AR Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate Mov Disord 1991 6 4 288-292 
Benazzouz A Gross C F&#233;ger J Boraud T Bioulac B Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys Eur J Neurosci 1993 5 4 382-389 
Wichmann T Bergman H DeLong MR The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism J Neurophysiol 1994 72 2 521-530 
Kleiner-Fisman G Fisman DN Sime E Saint-Cyr JA Lozano AM Lang AE Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease J Neurosurg 2003 99 3 489-495 
Weaver FM Follett K Stern M Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial JAMA 2009 301 1 63-73 
Follett KA Weaver FM Stern M Pallidal versus subthalamic deep-brain stimulation for Parkinson&#8217;s disease N Engl J Med 2010 362 22 2077-2091 
Mazzone P Lozano A Stanzione P Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson&#8217;s disease Neuroreport 2005 16 17 1877-1881 
Plaha P Gill SS Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson&#8217;s disease Neuroreport 2005 16 17 1883-1887 
Moro E Hamani C Poon YY Unilateral pedunculopontine stimulation improves falls in Parkinson&#8217;s disease Brain 2010 133 Pt 1 215-224 
Ferraye MU Deb&#251; B Fraix V Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson&#8216;s disease Brain 2010 133 Pt 1 205-214 
Benabid AL Chabardes S Mitrofanis J Pollak P Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson&#8217;s disease Lancet Neurol 2009 8 1 67-81 
Benabid AL Pollak P Gao D Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders J Neurosurg 1996 84 2 203-214 
Meissner W Leblois A Hansel D Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations Brain 2005 128 Pt 10 2372-2382 
Welter ML Houeto JL Bonnet AM Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients Arch Neurol 2004 61 1 89-96 
Xia R Berger F Piallat B Benabid AL Alteration of hormone and neurotransmitter production in cultured cells by high and low frequency electrical stimulation Acta Neurochir (Wien) 2007 149 1 67-73 
Harnack D Meissner W Jira JA Winter C Morgenstern R Kupsch A Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism Exp Neurol 2008 210 1 257-260 
Maesawa S Kaneoke Y Kajita Y Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons J Neurosurg 2004 100 4 679-687 
Temel Y Visser-Vandewalle V Kaplan S Protection of nigral cell death by bilateral subthalamic nucleus stimulation Brain Res 2006 1120 1 100-105 
Wallace BA Ashkan K Heise CE Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys Brain 2007 130 Pt 8 2129-2145 
Spieles-Engemann AL Behbehani MM Collier TJ Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss Neurobiol Dis 2010 39 1 105-115 
Bergman H Wichmann T Karmon B DeLong MR The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism J Neurophysiol 1994 72 2 507-520 
Crossman AR Mitchell IJ Sambrook MA Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey Neuropharmacology 1985 24 6 587-591 
Eidelberg D Moeller JR Dhawan V The metabolic topography of parkinsonism J Cereb Blood Flow Metab 1994 14 5 783-801 
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson&#8217;s disease N Engl J Med 2001 345 13 956-963 
Charles PD van Blercom N Krack P Predictors of effective bilateral subthalamic nucleus stimulation for PD Neurology 2002 59 6 932-934 
Deuschl G Schade-Brittinger C Krack P A randomized trial of deep-brain stimulation for Parkinson&#8217;s disease N Engl J Med 2006 355 9 896-908 
Volkmann J Deep brain stimulation for the treatment of Parkinson&#8217;s disease J Clin Neurophysiol 2004 21 1 6-17 
Morgante L Morgante F Moro E How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire Parkinsonism Relat Disord 2007 13 8 528-531 
Espay AJ Vaughan JE Marras C Fowler R Eckman MH Early versus delayed bilateral subthalamic deep brain stimulation for parkinson&#8217;s disease: a decision analysis Mov Disord 2010 25 10 1456-1463 
Deuschl G Controlled trial of deep brain stimulation in early patients with Parkinson&#8217;s disease Available from:
Charles PD Deep brain stimulation (DBS) for early stage Parkinson&#8217;s disease (PD) Available from:
Keeler CE Gene therapy J Hered 1947 38 10 294-298 
Morrow JF The prospects for gene therapy in humans Ann N Y Acad Sci 1976 265 13-21 
Nagatsu T Sawada M Biochemistry of postmortem brains in Parkinson&#8217;s disease: historical overview and future prospects J Neural Transm Suppl 2007 72 113-120 
Bankiewicz KS Forsayeth J Eberling JL Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC Mol Ther 2006 14 4 564-570 
Shen Y Muramatsu S Ikeguchi K Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson&#8217;s disease Hum Gene Ther 2000 11 11 1509-1519 
Muramatsu S Fujimoto K Ikeguchi K Behavioral recovery in a primate model of Parkinson&#8217;s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes Hum Gene Ther 2002 13 3 345-354 
Jarraya B Boulet S Ralph GS Dopamine gene therapy for Parkinson&#8217;s disease in a nonhuman primate without associated dyskinesia Sci Transl Med 2009 1 2 2ra4 
Oxford BioMedica announces two-year phase I/II results of ProSavin&#174; in Parkinson&#8217;s disease &#8211; 6/14/2010 Available from:
Palfi S Phase I/II study of the safety, efficacy and dose evaluation of ProSavin for the treatment of bilateral idiopathic Parkinson&#8217;s disease Available from:
Bankiewicz KS Eberling JL Kohutnicka M Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach Exp Neurol 2000 164 1 2-14 
Eberling JL Jagust WJ Christine CW Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 2008 70 21 1980-1983 
Muramatsu S Fujimoto K Kato S A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson&#8217;s disease Mol Ther 2010 18 9 1731-1735 
Stocchi F Ruggieri S Vacca L Olanow CW Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson&#8217;s disease Brain 2002 125 Pt 9 2058-2066 
Nutt JG Obeso JA Stocchi F Continuous dopamine-receptor stimulation in advanced Parkinson&#8217;s disease Trends Neurosci 2000 23 10 Suppl S109-S115 
Chase TN Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 1998 50 5 Suppl 5 S17-S25 
Carlsson T Winkler C Burger C Reversal of dyskinesias in an animal model of Parkinson&#8217;s disease by continuous L-DOPA delivery using rAAV vectors Brain 2005 128 Pt 3 559-569 
Kaplitt MG Feigin A Tang C Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#8217;s disease: an open label, phase I trial Lancet 2007 369 9579 2097-2105 
Stoessl AJ Gene therapy for Parkinson&#8217;s disease: early data Lancet 2007 369 9579 2056-2058 
Schapira AH Olanow CW Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 2004 291 3 358-364 
Lin LF Doherty DH Lile JD Bektesh S Collins F GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 1993 260 5111 1130-1132 
Nutt JG Burchiel KJ Comella CL Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 2003 60 1 69-73 
Kordower JH Palfi S Chen EY Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#8217;s disease Ann Neurol 1999 46 3 419-424 
Kirik D Rosenblad C Bjorklund A Mandel RJ Long-term rAA V-mediated gene transfer of GDNF in the rat Parkinson&#8217;s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system J Neurosci 2000 20 12 4686-4700 
Wang L Muramatsu S Lu Y Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson&#8217;s disease Gene Ther 2002 9 6 381-389 
Kordower JH Emborg ME Bloch J Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson&#8217;s disease Science 2000 290 5492 767-773 
Lo Bianco C D&#233;glon N Pralong W Aebischer P Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson&#8217;s disease Neurobiol Dis 2004 17 2 283-289 
Gill SS Patel NK Hotton GR Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 2003 9 5 589-595 
Patel NK Bunnage M Plaha P Svendsen CN Heywood P Gill SS Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study Ann Neurol 2005 57 2 298-302 
Lang AE Gill S Patel NK Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol. 2006;60(6):747] Ann Neurol 2006 59 3 459-466 
Gasmi M Herzog CD Brandon EP Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson&#8217;s disease Mol Ther 2007 15 1 62-68 
Gasmi M Brandon EP Herzog CD AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson&#8217;s disease Neurobiol Dis 2007 27 1 67-76 
Kordower JH Herzog CD Dass B Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys Ann Neurol 2006 60 6 706-715 
Marks WJ Jr Ostrem JL Verhagen L Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#8217;s disease: an open-label, phase I trial Lancet Neurol 2008 7 5 400-408 
Siffert J Double-blind, multicenter, sham surgery controlled study of CERE-120 in subjects with idiopathic Parkinson&#8217;s disease Available from:
Klejbor I Stachowiak EK Bharali DJ ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology J Neurosci Methods 2007 165 2 230-243 
Parkinson J An Essay on the Shaking Palsy London Sherwood, Neely and Jones 1817 
